Pharmacogenetics of advanced lung cancer: Predictive value of functional genetic polymorphism AGXT Pro11Leu in clinical outcome?

AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents. The association of genetic variant AGXT rs34116584 on the clinical outcome and response to chemotherapy of patients with non-small cell l...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonology 2021-03, Vol.27 (2), p.116-123
Main Authors: Catarata, Maria Joana, Lourenço, Margarida, Martins, Maria Fátima, Frade, João, Pêgo, Alice, Cordeiro, Carlos Robalo, Medeiros, Rui, Ribeiro, Ricardo
Format: Article
Language:English
Subjects:
Cohort study
Non-small cell lung cancer
Pharmacogenetics
Single nucleotide polymorphism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents. The association of genetic variant AGXT rs34116584 on the clinical outcome and response to chemotherapy of patients with non-small cell lung cancer (NSCLC) remains to be established. Our aim was to evaluate the association of functional AGXT gene polymorphism in NSCLC progression, considering as primary and secondary endpoint, progression free survival (PFS) and overall survival (OS), respectively. Genotyping of theAGXT rs34116584 genetic polymorphism was performed by mass spectrometry on 168 DNA samples from patients with NSCLC (stages IIIA-IVB). Univariate survival analysis included the study of Kaplan-Meier curves with the Log-Rank test, while Cox regression was used as a multivariate analysis. Multivariate analysis showed shorter PFS for T carriers [HR=2.0, 95% CI, 1.4−3.0, p
ISSN:2531-0437
2531-0437
DOI:10.1016/j.pulmoe.2020.11.007